Please ensure Javascript is enabled for purposes of website accessibility

Could Novavax, Inc. Be a Millionaire-Maker Stock?

By Keith Speights - Feb 16, 2018 at 5:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax is hot right now -- but just how much hotter could this biotech stock get?

All it takes for a stock to turn an initial investment of $10,000 into a cool $1 million is to double -- roughly seven times in a row. And that would give you several hundred thousand dollars left over.

That might seem like a tall order... and it is. However, it's been done before. In fact, an initial $10,000 investment in Warren Buffett's Berkshire Hathaway back in 1964 would be worth close to $240 million today.

Novavax (NVAX 11.12%) is no Berkshire Hathaway at this point. However, the clinical-stage biotech stock is up more than 60% so far in 2018. That's a good start. Could Novavax possibly be a millionaire-maker stock at some point down the road?   

Man holding magnet attracting cash

Image source: Getty Images.

Behind the tremendous momentum

Did Novavax stock zoom higher in recent weeks because of an announcement of great clinical results? Nope. Did the small biotech announce that it was getting bought out? No again, but we're getting warmer.

The impressive gain for Novavax so far in 2018 stemmed primarily from speculation that the company might be acquired by a larger player. The two names being floated as potential suitors are GlaxoSmithKline (GSK 0.51%) and Sanofi (SNY 1.96%). Interestingly, though, the rumors of a possible acquisition don't seem to have been driven primarily by Novavax's lead pipeline candidate.

Instead, a really nasty flu season has led some to suspect that GlaxoSmithKline and Sanofi could be interested in Novavax's experimental nanoparticle-based flu vaccine, NanoFlu. GSK's Flulaval and Fluarix and Sanofi's Flublok and Fluzone vaccines currently are the leaders in the flu market. However, Novavax announced encouraging pre-clinical results for its NanoFlu vaccine in August. Those results prompted the biotech to kick into high gear to advance the vaccine into clinical testing.

Both GlaxoSmithKline and Sanofi would be natural candidates to potentially buy Novavax. GSK's growth has been hampered by stagnant and declining sales for some of its older products, and it's a similar story for Sanofi. The French drugmaker has already announced one major acquisition this year with its purchase of Bioverativ. More deals wouldn't be surprising. 

Novavax's prospects

It's important to remember, though, that NanoFlu is currently only in early-stage testing. Novavax should announce results from its phase 1/2 study any day. If the study is successful, the company wants to quickly move to a late-stage study of the vaccine.

All we have to go on right now are the pre-clinical studies of NanoFlu conducted in ferrets. In those studies, NanoFlu generated better antibody responses than did Sanofi's Fluzone and Fluzone HD vaccines. There's still a few years to go, though, before NanoFlu could potentially be approved -- and that's if everything goes well in testing.

Still, if NanoFlu succeeds in clinical testing, it definitely has tremendous opportunities. The flu-vaccine market in the U.S. and six other developed nations tops $3 billion annually. The current flu season has definitely demonstrated the need for more effective treatments.

However, Novavax has another pipeline candidate that also has significant potential. And it could be even closer to approval. 

The biotech is currently evaluating its RSV F vaccine for maternal immunization of infants in a late-stage study. Novavax expects to announce results from this study by early 2019 and perhaps by the end of this year. If those results are positive and the vaccine wins regulatory approval, the company estimates worldwide peak sales for the RSV F vaccine could exceed $1.5 billion.   

Don't count on that million

Could Novavax be a millionaire-maker stock? Don't count on it.

I'm cautiously optimistic about Novavax's chances with NanoFlu and the RSV F vaccine. There are certainly risks that things won't go well, but my view is that the biotech could score with both pipeline candidates. However, the only way Novavax could make you $1 million, in my view, is if you started with an initial investment in the six figures.

My reasoning is simple: If NanoFlu is successful in the phase 1/2 study, I expect Novavax to be acquired -- probably by GlaxoSmithKline or Sanofi, just as some have speculated. If that doesn't happen, but the RSV F vaccine is successful in the current phase 3 study, I still expect the biotech to be acquired. Either way, my projection is that the price tag for Novavax will be well below what's needed to make most investors $1 million.

Will my predictions be accurate? We'll soon find out.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72
Sanofi Stock Quote
Sanofi
SNY
$51.01 (1.96%) $0.98
GSK Stock Quote
GSK
GSK
$43.75 (0.51%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.